

APC310Hu01 100µg
Active Adenine Phosphoribosyltransferase (APRT)
Organism Species: Homo sapiens (Human)
Instruction manual

FOR IN VITRO USE AND RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

1st Edition (Apr, 2016)

[PROPERTIES]

Source: Prokaryotic expression.

Host: *E. coli*

Residues: Met1~Glu180

Tags: N-terminal His-tag

Purity: >98%

Buffer Formulation: 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl and 5% trehalose.

Applications: Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

Predicted isoelectric point: 6.8

Predicted Molecular Mass: 23.3kDa

Accurate Molecular Mass: 23kDa as determined by SDS-PAGE reducing conditions.

[USAGE]

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

[SEQUENCE]

```
MADSELQLVE QRIRSFDFP TPGVVFRDIS PVLKDPASFR AAIGLLARHL  
KATHGGRIDY IAGLDSRGFL FGPSLAQELG LGCVLIRKRG KLPGPTLWAS  
YSLEYGKAEL EIQKDALEPG QRVVVVDDLL ATGGTMNAAC ELLGRLQAEV  
LECVSLVELT SLKGREKLAP VPFFSLLQYE
```

[ACTIVITY]

Adenine Phosphoribosyltransferase (APRT) is an enzyme involved in the purine nucleotide salvage pathway. It functions as a catalyst in the reaction between adenine and phosphoribosyl pyrophosphate (PRPP) to form AMP. Besides, Vascular Cell Adhesion Molecule 1 (VCAM1) has been identified as an interactor of APRT, thus a binding ELISA assay was conducted to detect the interaction of recombinant human APRT and recombinant human VCAM1. Briefly, APRT were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to VCAM1-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-APRT pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of APRT and VCAM1 was shown in Figure 1, and this effect was in a dose dependent manner.




Figure 1. The binding activity of APRT with VCAM1.

[IDENTIFICATION]




Figure 2. Gene Sequencing (extract)




Figure 3. SDS-PAGE

Sample: Active recombinant APRT, Human




Figure 4. Western Blot

Sample: Recombinant APRT, Human;

Antibody: Rabbit Anti-Human APRT Ab (PAC310Hu01)